Contraception Special Issue on the mifepristone Risk Evaluation and Mitigation Strategy (REMS)

Contraception. 2021 Jul;104(1):1-3. doi: 10.1016/j.contraception.2021.05.012.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Abortifacient Agents, Steroidal*
  • Contraception
  • Humans
  • Mifepristone*
  • Risk Assessment
  • Risk Evaluation and Mitigation
  • United States
  • United States Food and Drug Administration

Substances

  • Abortifacient Agents, Steroidal
  • Mifepristone